Royal Bank Of Canada Intercept Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $34,035 - $63,744	3,407 Added 114.91%	6,372 $118,000
Q2 2023 Aug 14, 2023	SELL	$9.17 - $19.29 $49,637 - $104,416	-5,413 Reduced 64.61%	2,965 $32,000
Q1 2023 May 15, 2023	SELL	$12.53 - $21.71 $58,251 - $100,929	-4,649 Reduced 35.69%	8,378 $112,000
Q4 2022 Feb 14, 2023	BUY	$11.61 - $16.11 $28,908 - $40,113	2,490 Added 23.63%	13,027 $161,000
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $2,002 - $3,230	164 Added 1.58%	10,537 $147,000

Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $15,665 - $27,328	-1,395 Reduced 11.85%	10,373 $144,000
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $74,136 - $98,645	-5,545 Reduced 32.03%	11,768 $191,000
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $48,966 - $66,968	3,429 Added 24.7%	17,313 $281,000
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $861,340 - $1.36 Million	-66,308 Reduced 82.69%	13,884 $206,000
Q2 2021 Aug 16, 2021	BUY	$15.46 - $24.5 $1.24 Million - $1.96 Million	80,192 New	80,192 $1.6 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.